Skip to content

Depression: all studies

Page 347 of 1,040: studies 3,461 to 3,470 of 10,391, newest first. Back to the depression overview

Research

The Effectiveness of Mindfulness-Based Interventions for Depressive Symptoms and Their Relationship to Interoceptive Awareness: A Systematic Review.

Alpha psychiatry December 1, 2025 Samantha Knep, Alice Shires 1 citation

This systematic review aimed to investigate the effectiveness of mindfulness-based interventions (MBIs) in treating depression, enhancing interoceptive awareness (IA), and whether IA mediates this relationship. In August 2024, a comprehensive literature search was conducted in web-based medical and psychological databases, including PsycINFO, MEDLINE, and Scopus, following the Preferred...

Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.

Cureus December 1, 2025 Paweł Liszka, Agata Ogórek, Klaudia M Olejnik-Chlewicka et al.

Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry as potential therapeutic tools. The aim of this paper is to review current data on their mechanisms of action, clinical applications in the treatment of mood and anxiety disorders, addictions and post-traumatic stress disorder (PTSD), as well as to...

Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder.

European Journal of Psychotraumatology December 1, 2025 Gabrielle Agin-Liebes, Richard J. Zeifman, Jennifer Mitchell 11 citations

Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcohol use disorder, and substance use disorders. A well-powered phase 3 randomized, placebo-controlled trial has shown that MDMA-assisted therapy (MDMA-AT) may be an effective treatment for severe PTSD. However, the psychological mechanisms driving the...

Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical Practice.

Clinical Psychopharmacology and Neuroscience November 30, 2025 Alessandro Serretti 2 citations

Depression is increasingly conceptualized as a disorder of impaired synaptic plasticity and excitation-inhibition imbalance within corticolimbic circuits. Two rapid-acting therapeutic classes, NMDA receptor modulators (ketamine, esketamine) and neuroactive-steroid GABA-A positive allosteric modulators (brexanolone, zuranolone), offer complementary approaches to restore circuit function....

DOI: 10.9758/cpn.25.1349 (opens in new tab) Full text (opens in new tab) Antidepressive agents Depression, postpartum Neurosteroids

A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model

Scientific Reports November 26, 2025 Małgorzata Domżalska, Joanna Kwiatkowska, Iwona Cichoń et al. 2 citations

Depression is a debilitating mental disorder affecting millions worldwide, yet current pharmacological treatments, such as selective serotonin reuptake inhibitors (SSRIs), often exhibit delayed onset and limited efficacy. The chronic social defeat (CSD) stress model in mice is a well-established preclinical paradigm for inducing depression-like behaviors and evaluating antidepressants...

Lost in Speech: Depressive Rumination and the Dynamics of Inner Silence.

Inquiry November 14, 2025 Dan Degerman, Jae Ryeong Sul 1 citation

This paper clarifies the experiential profile of depressive rumination, a form of repetitive and persistent negative thinking that is phenomenologically and aetiologically central in depression. Phenomenological analyses of depression have generally remained too high-level to account for this centrality. Drawing on first-person depression narratives and recent philosophy of psychiatry and...

Ascorbic acid enhances antidepressant-like efficacy of esketamine: Hippocampal TARP-γ8-containing AMPA receptors mediate synaptic modulation.

Neurotherapeutics November 11, 2025 Zhaojuan Ke, Ying Zhang, Xin Jiang et al.

Ketamine exhibits superior efficacy compared to conventional antidepressants, yet its clinical application remains limited by dose-dependent side effects. Ascorbic acid (AA) augments ketamine's antidepressant-like effects, suggesting that AA co-administration with subtherapeutic ketamine doses may achieve optimal efficacy while improving safety. Since AA itself lacks independently clinical...

Advancements in psychedelic research: Effects, mechanisms, and therapeutic potential as emerging antidepressants.

Pharmacology, Biochemistry, and Behavior November 1, 2025 Xian-Qiang Zhang, De-Nong Liu, Qing-Shan Miao et al.

Major depressive disorder (MDD) causes great physical and mental suffering to patients while also imposing a tremendous economic burden on the global economy. Psychedelics, also known as serotonergic hallucinogens, are potent psychoactive compounds known for their ability to alter mood, perception, and a range of cognitive functions. Increasing evidence suggests that some psychedelics...

Is poor dose selection undermining the translational validity of antidepressant research involving animal models?

bioRxiv (Cold Spring Harbor Laboratory) November 1, 2025 Dasha Anderson, Justyna K. Hinchcliffe, Megan N. Jackson et al. 1 citation preprint

Abstract Background Behavioural studies in animal models represent a critical component of psychiatric drug development. Positive results in animal studies have identified novel therapeutic targets for major depressive disorder (MDD) but efficacy in humans has largely not been borne out in clinical trials. A possible reason for this failed translation is inappropriate dose selection and the...

The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness-Based Cancer Recovery (e-MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled Trial.

Psycho-Oncology November 1, 2025 Marie-Estelle Gaignard, Dominica Martin, Jelena Stanic et al.

Mindfulness-Based Interventions (MBIs) are recognized as beneficial in oncology supportive care. While qualitative analyses of mindfulness program experiences exist, this is the first mixed methods study to examine patients' experiences after participating in the online Mindfulness-Based Cancer Recovery (e-MBCR) program. The SERENITY study was a pilot randomized controlled trial evaluating the...

DOI: 10.1002/pon.70334 (opens in new tab) Full text (opens in new tab) Depression Mindfulness program Digital mindfulness-based recovery Online mindfulness support +14